



## Announcement Summary

---

**Entity name**

CRESO PHARMA LIMITED

**Announcement Type**

New announcement

**Date of this announcement**

Monday August 29, 2022

**The +securities to be quoted are:**

+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B

**Total number of +securities to be quoted**

ASX +security code	Security description	Number of +securities to be quoted	Issue date
CPH	ORDINARY FULLY PAID	100,000	29/08/2022

Refer to next page for full details of the announcement



## Part 1 - Entity and announcement details

---

### 1.1 Name of entity

CRESO PHARMA LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

### 1.2 Registered number type

ABN

### Registration number

89609406911

### 1.3 ASX issuer code

CPH

### 1.4 The announcement is

New announcement

### 1.5 Date of this announcement

29/8/2022



## Part 2 - Type of Issue

---

### 2.1 The +securities to be quoted are:

+Securities issued as part of a transaction or transactions previously announced to the market in an Appendix 3B

### Previous Appendix 3B details:

Announcement Date and Time	Announcement Title	Selected Appendix 3B to submit quotation request
15-Aug-2022 09:55	New - Proposed issue of securities - CPH	<input type="text" value="A placement or other type of issue"/>

### 2.3a.2 Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B?

Yes

### 2.3a.3 Please provide details of the further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B

As set out in the Appendix 3B dated 15 August 2022, the Company will seek shareholder approval for the issue of 2 million performance rights at a future General Meeting.



Part 3A - number and type of +securities to be quoted where issue has previously been notified to ASX in an Appendix 3B

---

Placement Details

---

**ASX +security code and description**

CPH : ORDINARY FULLY PAID

**Issue date**

29/8/2022

Distribution Schedule

---

**Provide a distribution schedule for the new +securities according to the categories set out in the left hand column - including the number of recipients and the total percentage of the new +securities held by the recipients in each category.**

<b>Number of +securities held</b>	<b>Number of holders</b>	<b>Total percentage of +securities held</b> For example, to enter a value of 50% please input as 50.00
1 - 1,000		%
1,001 - 5,000		%
5,001 - 10,000		%
10,001 - 100,000		%
100,001 and over		%



Issue details

---

**Number of +securities to be quoted**

100,000

**Are the +securities being issued for a cash consideration?**

No

**Please describe the consideration being provided for the +securities**

100,000 shares issued to Kolby Tullier (or his nominee), as part consideration for his services under his Brand Ambassador and Strategic Adviser Agreement with subsidiary, Creso Pharma ImpACTIVE Ltd.

**Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted**

3,600.000000

**Any other information the entity wishes to provide about the +securities to be quoted**

Please note that due to delays in ASX forms processing, the issued capital below does not reflect the issue of 357,614,203 CPH shares (per the Appendix 2A lodged on the same date as this form) and 6,000,000 Performance Shares (per the Appendix 3G lodged on the same date as this form). This means that the current number of CPH Ordinary Shares is 1,785,707,156.





## Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

**4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
CPHOA : OPTION EXPIRING 22-JAN-2023	63,958,997
CPH : ORDINARY FULLY PAID	1,428,092,953
CPHO : OPTION EXPIRING 02-NOV-2024	400,941,788

**4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)**

<b>ASX +security code and description</b>	<b>Total number of +securities on issue</b>
CPHAAN : OPTION EXPIRING 06-SEP-2024 EX \$0.25	10,000,000
CPHA AO : PERFORMANCE RIGHTS	15,000,000
CPHAY : OPTION EXPIRING 02-JUN-2023 EX 17C	27,764,706
CPHAAA : OPTION EXPIRING 02-JUN-2023 EX 20C	8,000,000
CPHAZ : OPTION EXPIRING 02-JUN-2023 EX 25C	4,000,000
CPHAQ : OPTION EXPIRING 15-SEP-2022 EX 80C	300,000
CPHAAB : OPTION EXPIRING 25-JUN-2023 EX 13.86C	5,752,688
CPHAAL : OPTION EXPIRING 01-AUG-2024 EX \$0.18	12,000,000
CPHAS : OPTION EXPIRING 12-FEB-2023 EX 40C	6,847,725
CPHAT : OPTION EXPIRING 12-FEB-2023 EX 35C	2,128,387
CPHAAK : OPTION EXPIRING 01-AUG-2024 EX \$0.15	12,000,000



CPHAAM : OPTION EXPIRING 06-SEP-2024 EX \$0.18	10,000,000
CPHAM : PERFORMANCE RIGHTS	799,000
CPHAAC : OPTION EXPIRING 11-JAN-2023 EX \$0.235	8,000,000
CPHAAD : OPTION EXPIRING 11-JAN-2023 EX \$0.27	8,000,000
CPHAAE : OPTION EXPIRING 11-JAN-2023 EX \$0.30	8,000,000
CPHAAF : OPTION EXPIRING 11-JAN-2023 EX \$0.40	2,800,000
CPHAAG : OPTION EXPIRING 23-DEC-2023 EX \$0.20	833,333
CPHAAH : OPTION EXPIRING 23-DEC-2025 EX \$0.039	30,000,000
CPHAU : OPTION EXPIRING 01-MAR-2023 EX 25C	250,000
CPHAAI : OPTION EXPIRING 14-JUL-2024 EX \$0.38	12,000,000
CPHAAP : OPTION EXPIRING 25-OCT-2024 EX \$0.1375	1,000,000